

Human BTN3A2 Protein

Cat. No. BNT-HM2A2

Description

Source	Recombinant Human BTN3A2 Protein is expressed from HEK293 with hFc tag at the C-terminus. It contains Gln30-Trp248.
Accession	P78410-1
Molecular Weight	The protein has a predicted MW of 50.37 kDa. Due to glycosylation, the protein migrates to 52-65 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage

Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial ovarian cancer (HG-EOC). In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with better outcome. In contrast, high CD206 /CD68 expression is associated with high risk of disease progression.


Assay Data

Tris-Bis PAGE



Human BTN3A2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human BTN3A2 is greater than 95% as determined by SEC-HPLC.